𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma : A Phase II FONICAP trial

✍ Scribed by Maria Cristina Pennucci; Andrea Ardizzoni; Paolo Pronzato; Marina Fioretti; Claudio Lanfranco; Anna Verna; Guglielmina Giorgi; Antonella Vigani; Carlo Frola; Riccardo Rosso

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
182 KB
Volume
79
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

and cisplatin (P) yielded an objective response rate of 25% and a subjective response rate of 50% in patients with mesothelioma. In human mesothelioma cell

πŸ“œ SIMILAR VOLUMES

Cisplatin in combination with irinotecan
Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma : A pilot phase II clinical trial and pharmacokinetic profile
✍ Takashi Nakano; A. Philippe Chahinian; Miho Shinjo; Naoki Togawa; Atsushi Tonomu πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 161 KB πŸ‘ 1 views

The purpose of this study was to assess the efficacy and toxicity of a combination of cisplatin and irinotecan (CPT-11) in the treatment of patients with malignant pleural mesothelioma and to characterize the pharmacokinetic profiles of CPT-11 and its active metabolite, 7-ethyl-10-hydroxycamptotheci

Phase II study of a modified combination
Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer
✍ IΓ§li, Fikri; Karaoguz, Handan; Akbulut, Hakan; DinΓ§ol, Dilek; Demirkazik, Ahmet; πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 52 KB πŸ‘ 2 views

## Background: Based on the promising results of eap (etoposide, doxorubicin, and cisplatin) combination, a phase ii study of modified eap combination was performed in patients with advanced gastric cancer to evaluate the response, toxicity, and survival. ## Method: Fifty-two consecutive patients

A phase II trial of neoadjuvant methotre
A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma
✍ Louise E. Morrell; Young J. Lee; Judith Hurley; Mayda Arias; Carolyn Mies; Steph πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 104 KB πŸ‘ 2 views

## Background: Traditionally, primary surgical therapy is considered unsuitable for the treatment of patients with locally advanced breast carcinoma (labc). multiple reports have documented the efficacy of primary chemotherapy in this group of patients. the purpose of this study was to investigate

The combination of cisplatin, doxorubici
The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma: A phase II randomized trial of the Italian oncology group for clinical research
✍ Vincenzo De Lisi; Giorgio Cocconi; Francesco Angelini; Francesco Cavicchi; Franc πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 482 KB πŸ‘ 2 views

## BACKGROUND. In a randomized Phase I1 study, the authors evaluated the activity and toxicity of the new cisplatin, doxorubicin, and mitomycin C (PAM) comhination, that includes cisplatin (P) instead of 5-fluorouracil as in the 5-fluorouracil, doxorubicin, and mitomycin C (FAM) Combination, in pat